- Resource
- BR1DGE
- Pathophysiology
- Management
- Video
Immune Dysregulation in T1D: Biomarkers and Therapeutic Targets
Profs. Kay and Bonifacio discuss the role of T-cell dysregulation as a central pathophysiological mechanism in T1D, and its implications for emerging therapies and biomarkers
Learning Objectives
- Understand the underlying immune dysregulation in T1D
- Explore how immune dysregulation offers opportunities for the development of disease modifying therapies and biomarkers of disease
Summary
At IDS, Professors Kay, Mathieu, and Bonifacio discussed the role of T-cell dysregulation as a central pathophysiological mechanism in T1D, and its implications for emerging therapies and biomarkers.
While advances in immunology have introduced novel therapeutics such as bispecific antibodies and CAR-T cells, leveraging T-cells as reliable biomarkers in T1D remains an unresolved challenge. Professors Kay and Bonifacio noted that neither T-cell count nor antigen-specific T-cell numbers have proven sufficient as progression markers. A key barrier is the lack of standardization in T-cell assays. Beyond T-cells, other cellular markers such as B cells and neutrophils warrant further investigation: the development of robust, clinically applicable cellular biomarkers of T1D remains a work in progress.
MAT-GLB-2600299 - 1.0 - 06/2026
Early T1D Screening Recommendations
Expert insights on recommendations for T1D screening, including proposed age ranges and opportunities for integration into existing public health touchpoints.
Supporting islet-autoantibody-positive individuals and their families
Appropriate strategies can help support people with early-stage T1D and their families and address anxiety during early T1D monitoring, ensuring optimal engagement and care.